BrightPath Biotherapeutics Co., Ltd.

Tokyo Stock Exchange 4594.T

BrightPath Biotherapeutics Co., Ltd. Capital Expenditure for the year ending March 31, 2024: USD -50.53 K

BrightPath Biotherapeutics Co., Ltd. Capital Expenditure is USD -50.53 K for the year ending March 31, 2024, a -281.43% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

BrightPath Biotherapeutics Co., Ltd. Capital Expenditure for the year ending March 31, 2023 was USD -13.25 K, a 90.86% change year over year.
BrightPath Biotherapeutics Co., Ltd. Capital Expenditure for the year ending March 31, 2022 was USD -144.96 K, a 54.49% change year over year.
BrightPath Biotherapeutics Co., Ltd. Capital Expenditure for the year ending March 31, 2021 was USD -318.52 K, a 68.90% change year over year.
BrightPath Biotherapeutics Co., Ltd. Capital Expenditure for the year ending March 31, 2020 was USD -1.02 M, a 35.21% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Tokyo Stock Exchange: 4594.T

BrightPath Biotherapeutics Co., Ltd.

CEO	Mr. Kenichi Nagai
IPO Date	Oct. 22, 2015
Location	Japan
Headquarters	Kojimachi Central Building
Employees	42
Sector	Healthcare
Industries Biotechnology 3D Printing Pharmaceuticals Vaccines

Description

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years